AstraZeneca Pharma India has reported a strong 30% year-on-year growth in the second quarter of FY2026-27, with revenue from ...
Brazil's health regulator ANVISA approved Dr. Reddy's Laboratories to market a generic semaglutide injection for adults with ...
Supriya Lifescience Ltd. reported a standalone net profit of Rs. 29.25 crore for the second quarter ended September 30, 2026, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results